The investigational monoclonal antibody bentracimab “immediately and significantly” reversed the antiplatelet effects of ticagrelor in older people in an interim analysis of a Phase IIb trial, showing the drug candidate’s promise for P2Y12 patients with major bleeding who require urgent intervention.